Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2287]

PROMISE-meso trial results: Pembrolizumab vs chemotherapy for advanced pleural...

Prof Sanjay Popat - The Royal Marsden Hospital, London, UK

PROMISE-meso trial results: Pembrolizumab vs chemotherapy for advanced pleural mesothelioma ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )

Checkmate 227: Final analysis for the non small cell lung cancer trial

Prof Sanjay Popat - The Royal Marsden Hospital, London, UK

Checkmate 227: Final analysis for the non small cell lung cancer trial ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )

PARP inhibitors for metastatic breast cancer

Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany

PARP inhibitors for metastatic breast cancer ( Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany )

KATHERINE trial updates for HER2-positive breast cancer

Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany

KATHERINE trial updates for HER2-positive breast cancer ( Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany )

Lutetium-177 PSMA scanning for prostate cancer

Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA

Lutetium-177 PSMA scanning for prostate cancer ( Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA )

Highlights from ESMO 2019

Prof Josep Tabernero - ESMO President

Highlights from ESMO 2019 ( Prof Josep Tabernero - ESMO President )

AMG 510: A novel molecule targeting KRAS G12C mutant solid tumours

Prof Marwan Fakih - City of Hope National Medical Center, Duarte, USA

AMG 510: A novel molecule targeting KRAS G12C mutant solid tumours ( Prof Marwan Fakih - City of Hope National Medical Center, Duarte, USA )

MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast...

Prof Susan Domchek - University of Pennsylvania, Pennsylvania, USA

MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast cancer ( Prof Susan Domchek - University of Pennsylvania, Pennsylvania, USA )

Blood first assay screening in patients with ALK positive NSCLC

Prof Shirish Gadgeel - University of Michigan, Ann Arbor, USA

Blood first assay screening in patients with ALK positive NSCLC ( Prof Shirish Gadgeel - University of Michigan, Ann Arbor, USA )

Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative...

Dr Véronique Diéras - Centre Eugène Marquis, Rennes, France

Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer ( Dr Véronique Diéras - Centre Eugène Marquis, Rennes, France )

CUPISCO: Identifying carcinoma of unknown primary patients according to ESMO...

Prof Jeffrey S. Ross - Albany Medical Center, Albany, USA

CUPISCO: Identifying carcinoma of unknown primary patients according to ESMO guidelines ( Prof Jeffrey S. Ross - Albany Medical Center, Albany, USA )

CheckMate 459: Safety and efficacy of nivolumab versus sorafenib as a first...

Dr Thomas Yau - The University of Hong Kong, Hong Kong

CheckMate 459: Safety and efficacy of nivolumab versus sorafenib as a first-line treatment in advanced hepatocellular carcinoma ( Dr Thomas Yau - The University of Hong Kong, Hong Kong )

More from ecancer